Today Eccogene announces that it has completed a new series financing of more than 100 million RMB, co-led by Delos Capital and Oriza Seed, with participation from new investors HuaGai Capital, Tsing Song Capital and existing investor Sinopharm Capital. The raised fund will support clinical and preclinical development of several metabolic drug candidates, and continuous advancement of Eccogene‘s pipeline programs. “Addressing unmet medical needs by differentiated product profile and innovative R&D capability, is the cornerstone to gain trust and support from prestigious investors. The new series of financing will enable Eccogene’s transition to a clinical stage company and accelerate clinical development of its leading programs to bring innovative therapeutic solutions to patients as early as we can.” said Dr. Jingye Zhou, Chairman and CEO of Eccogene.
Eccogene was founded in 2018 by seasoned drug hunters with extensive R&D experience in top pharmaceutical companies and track record of discovery of FDA approved drug.
Eccogene focuses on discovery and development of translational medicine in metabolic and immune-related diseases, specialized in disease biology, medicinal chemistry, and translational science to advance its novel and differentiated pipeline to address unmet medical needs globally.
Previously, Eccogene raised 100 million RMB financing in 2018, invested by Sinopharm Capital, TF Capital and Medfine Capital. For more information, please visit Eccogene’s website: http://www.eccogene.com/.
About Delos Capital
Delos Capital is a healthcare-focused fund, investing in growth platforms in Greater China and relevant innovation in the U.S. in both therapeutics and medical technology areas. Delos Capital seeks to achieve returns through supporting these companies in their development and also helping to create additional value from collaboration between these companies. With the extensive expertise and experience in both Greater China and the US, Delos Capital believes that it is well positioned to help with such collaboration. Delos Capital currently manages two funds, with over US$ 330 million in total capital under management. For more information, please visit Delos Capital’s website: https://www.deloscapital.com/.
About Oriza Seed
Oriza Seed is a professional early-stage equity investment platform of Oriza Holdings, focusing on investing early-stage and growth-stage start-ups in the Healthcare and TMT industries. Oriza Seed manages ten VC funds and angel funds with about 3.5 billion assets under management.
Oriza Seed has been widely recognized by early hi-tech start-ups and entrepreneurs. Currently, Oriza Seed has supported more than 180 companies, including Ascentage pharma, CStone Pharmaceuticals, JW Therapeutics, BR Robot, Tztek, Cambricon, Crystal Pharmatech, Basecare, Singleron, Sprideradio, Cloudwalk, Mogulinker, etc. For more information, please visit Oriza Seed’s website: http://www.oriza.com.cn/.